J. Safra Sarasin Holding AG Lowers Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Key Points

• J. Safra Sarasin Holding AG reduced its stake in Alnylam Pharmaceuticals by 14.1% during the first quarter, with holdings now valued at $4.44 million.
• Despite the decline in shares owned by J. Safra Sarasin, other institutional investors have increased their positions significantly, with Capital Research Global Investors boosting holdings by 32.9%.
• Alnylam Pharmaceuticals reported a loss of $0.44 EPS, which was lower than expected, yet its revenue for the quarter grew 20.2% year-over-year, totaling $594.19 million.

J. Safra Sarasin Holding AG trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 14.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,435 shares of the biopharmaceutical company's stock after selling 2,707 shares during the period. J. Safra Sarasin Holding AG's holdings in Alnylam Pharmaceuticals were worth $4,438,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Privium Fund Management B.V. purchased a new position in shares of Alnylam Pharmaceuticals in the 1st quarter worth about $1,543,000. PNC Financial Services Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 4.7% during the first quarter. PNC Financial Services Group Inc. now owns 13,125 shares of the biopharmaceutical company's stock valued at $3,544,000 after acquiring an additional 585 shares in the last quarter. Commerce Bank lifted its position in Alnylam Pharmaceuticals by 1.2% in the 1st quarter. Commerce Bank now owns 4,557 shares of the biopharmaceutical company's stock valued at $1,230,000 after acquiring an additional 55 shares in the last quarter. Tredje AP fonden boosted its stake in Alnylam Pharmaceuticals by 63.3% during the 1st quarter. Tredje AP fonden now owns 15,907 shares of the biopharmaceutical company's stock valued at $4,295,000 after purchasing an additional 6,165 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter worth $402,000. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Trading Up 0.9%

Shares of NASDAQ ALNY traded up $3.72 during trading hours on Thursday, hitting $431.86. 323,862 shares of the company traded hands, compared to its average volume of 933,519. The company's 50 day moving average price is $326.26 and its 200 day moving average price is $282.20. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $436.77. The stock has a market capitalization of $56.61 billion, a price-to-earnings ratio of -175.25 and a beta of 0.25. The company has a current ratio of 2.80, a quick ratio of 2.98 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business had revenue of $773,689 billion for the quarter, compared to analysts' expectations of $633.54 million. During the same quarter in the previous year, the business posted ($0.13) earnings per share. The business's revenue was up 17.3% compared to the same quarter last year. On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the transaction, the chief executive officer owned 48,948 shares of the company's stock, valued at approximately $14,978,088. This represents a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Raymond James Financial started coverage on Alnylam Pharmaceuticals in a report on Wednesday, July 30th. They set an "outperform" rating and a $370.00 price target on the stock. Scotiabank boosted their price objective on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a "sector outperform" rating in a report on Friday, August 1st. BMO Capital Markets lifted their target price on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 24th. Wall Street Zen raised Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Finally, Barclays upped their target price on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a report on Friday, August 1st. Four investment analysts have rated the stock with a hold rating and twenty-four have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $403.92.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.